We’ve recently updated our valuation analysis.

Cue Health Valuation

Is HLTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLTH?

Other financial metrics that can be useful for relative valuation.

HLTH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.2x
Enterprise Value/EBITDA-1.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does HLTH's PS Ratio compare to its peers?

The above table shows the PS ratio for HLTH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.1x
LMDX LumiraDx
0.9x16.5%US$311.3m
CVRX CVRx
15.3x33.6%US$343.1m
ZYXI Zynex
3.6x22.5%US$533.0m
SGHT Sight Sciences
8.4x24.2%US$552.3m
HLTH Cue Health
0.7x8.3%US$372.1m

Price-To-Sales vs Peers: HLTH is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (7.1x).


Price to Earnings Ratio vs Industry

How does HLTH's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.4%
n/an/an/a

Price-To-Sales vs Industry: HLTH is good value based on its Price-To-Sales Ratio (0.7x) compared to the US Medical Equipment industry average (3.8x)


Price to Sales Ratio vs Fair Ratio

What is HLTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLTH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.7x
Fair PS Ratio0.7x

Price-To-Sales vs Fair Ratio: HLTH is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).


Share Price vs Fair Value

What is the Fair Price of HLTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLTH ($2.49) is trading below our estimate of fair value ($3.28)

Significantly Below Fair Value: HLTH is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLTH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.49
US$6.25
+151.0%
23.7%US$8.00US$4.00n/a4
Jan ’24US$2.07
US$6.50
+214.0%
23.1%US$8.00US$4.00n/a4
Dec ’23US$2.99
US$6.50
+117.4%
23.1%US$8.00US$4.00n/a4
Nov ’23US$4.01
US$8.00
+99.5%
15.3%US$9.00US$6.00n/a4
Oct ’23US$3.01
US$8.25
+174.1%
10.1%US$9.00US$7.00n/a4
Sep ’23US$3.50
US$8.25
+135.7%
10.1%US$9.00US$7.00n/a4
Aug ’23US$3.25
US$9.50
+192.3%
15.8%US$11.00US$7.00n/a4
Jul ’23US$3.07
US$9.88
+221.7%
9.0%US$11.00US$8.50n/a4
Jun ’23US$4.82
US$9.88
+104.9%
9.0%US$11.00US$8.50n/a4
May ’23US$6.70
US$10.88
+62.3%
12.3%US$13.00US$9.50n/a4
Apr ’23US$6.09
US$10.88
+78.6%
12.3%US$13.00US$9.50n/a4
Mar ’23US$9.08
US$13.50
+48.7%
15.3%US$16.00US$11.00n/a4
Feb ’23US$9.20
US$14.00
+52.2%
19.6%US$18.00US$11.00US$2.494
Jan ’23US$13.41
US$15.50
+15.6%
14.8%US$18.00US$12.00US$2.074
Dec ’22US$11.02
US$15.50
+40.7%
14.8%US$18.00US$12.00US$2.994
Nov ’22US$10.34
US$14.67
+41.8%
17.0%US$18.00US$12.00US$4.013

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies